Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study. in BMC ophthalmology / BMC Ophthalmol. 2024 Oct 4;24(1):436. doi: 10.1186/s12886-024-03706-0.

2024
ASL Torino 5
AO Ordine Mauriziano

Tipo pubblicazione

Journal Article

Autori/Collaboratori (9)Vedi tutti...

Bacherini D
Ophthalmology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Giansanti F
Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Rizzo S
Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

et alii...

Abstract

BACKGROUND: to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV). Both naïve and previously treated (i.e., switched) patients were included, and the data from the two groups were compared. METHODS: anatomical (i.e., central subfoveal thickness, CST; presence of fluid), functional (i.e., best corrected visual acuity, BCVA) and treatment-related (i.e., number of IV injections within the study period; number of patients reaching a 12-weeks interval between treatments) data from 41 eyes of 41 subjects (20 naïve and 21 switched) were analyzed. Patients were treated with 3 monthly IV injections followed by a T&E regimen based on a disease activity assessment performed at each scheduled IV treatment. RESULTS: significant CST reduction (from 412.1?±?115.8 to 273.2?±?61.6; p?